| Objective: To detect the serum levels of dickkopf-1(DKK-1) andtartrate-resistant acid phosphatase5b (TRACP-5b) in patients with Ankylosing Spondylitis(AS) before and after tumor necrosis factor alpha (TNF-α) inhibitors treatment, analyze therelevance between DKK-1， TRACP-5b and activity indexes of AS, investigate thepossible role of DKK-1and TRACP-5b in structural damage of AS.Methods: The subjects were30ankylosing spondylitis.15were injected TNF-αinhibitor (infliximab), and15were received thalidomide. The controls were20healthyindividua1s. ELISA was used to detect the levels of DKK-1and TRACP-5b in serum. Thecore indicators of AS such as gender, age, the course of disease, the patients’ pain score,morning stiffness, occipital-wall distance, finger-floor distance, erythrocyte sedimentationrate (ESR), C-reactive protein (CRP), BASDAI, and different radiographic stages wereevaluated. Contrast the serum levels of DKK-1and TRACP-5b in two groups includingbefore and after treatment and controls, analyze the relevance of DKK-1, TRACP-5b andthe core indexes of AS.Results:1. The levels of serum DKK-1and TRACP-5b in AS are819.65±204.56pg/mL and3.9393±1.3354U/L, significantly lower than which in controlgroup (1591.5±335.92pg/mL and8.6379±1.9148U/L, P<0.05);2. The levels of serumDKK-1and TRACP-5b of early AS are1186±493.7pg/mL and5.915±2.9282U/L, higherthan that of medium and late AS (636.6±181.04pg/mL and2.9614±1.3772U/L), but therewas no significance between them (P>0.05);3. The levels of serum DKK-1in infliximabgroup before and after treatment were875.49±280.48pg/mL and695.15±267.71pg/mL,but there was no statistical significance (P>0.05); there was significant difference between the levels of serum TRACP-5b of which (4.5949±2.0735U/L and3.2882±1.6406U/L,P<0.05).4. In thalidomide group, the differences were insignificant both in the levels ofserum DKK-1(763.81±306.98pg/Ml and642.39±232.26pg/mL) and serum TRACP-5b(3.2836±1.74U/L and2.9471±1.5647U/L) before and after treatment (P>0.05);5. Thelevels of serum DKK-1and TRACP-5b were both negatively correlated with theradiographic stage in patients with AS (P<0.05);6. There was positive correlation betweenthe level of serum DKK-1and TRACP-5b in patients with AS (P<0.0001).Conclusion:1. Significantly decreased serum levels of DKK-1and TRACP-5b werefound in AS compared with that of healthy controls showed that they may take part in theprogression of AS.2. After treat with infiliximab, there was decreasing in level of serumTRACP-5b and no change in that of DKK-1. It showed that TNF-α inhibitor may suppressthe bone loss, but has no effect on bone formation.3. There was no correlation betweenDKK-1, TRACP-5b and the marker of AS disease activity and inflammation, showed thatthe structural damage may be separated with inflammation and disease activity.4. Levelsof serum DKK-1and TRACP-5b may reflect the radiographic progression of AS as a resultof the negative correlation with radiographic stage. |
PDF Full Text Request